company background image
CREO

Creo MedicalAIM:CREO Stock Report

Market Cap

UK£280.5m

7D

-2.5%

1Y

5.7%

Updated

25 Sep, 2021

Data

Company Financials +
CREO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CREO Overview

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom.

Price History & Performance

Summary of all time highs, changes and price drops for Creo Medical
Historical stock prices
Current Share PriceUK£1.78
52 Week HighUK£1.38
52 Week LowUK£2.36
Beta1.11
1 Month Change-3.01%
3 Month Change-12.78%
1 Year Change5.66%
3 Year Change-21.11%
5 Year Changen/a
Change since IPO121.88%

Recent News & Updates

Shareholder Returns

CREOGB Medical EquipmentGB Market
7D-2.5%0.4%0.6%
1Y5.7%3.6%23.4%

Return vs Industry: CREO exceeded the UK Medical Equipment industry which returned 3.6% over the past year.

Return vs Market: CREO underperformed the UK Market which returned 23.4% over the past year.

Price Volatility

Is CREO's price volatile compared to industry and market?
CREO volatility
CREO Beta1.11
Industry Beta0.57
Market Beta1

Stable Share Price: CREO is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CREO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003217Craig Gullifordhttps://creomedical.com

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues.

Creo Medical Fundamentals Summary

How do Creo Medical's earnings and revenue compare to its market cap?
CREO fundamental statistics
Market CapUK£280.45m
Earnings (TTM)-UK£20.32m
Revenue (TTM)UK£9.43m

29.7x

P/S Ratio

-13.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CREO income statement (TTM)
RevenueUK£9.43m
Cost of RevenueUK£5.39m
Gross ProfitUK£4.03m
ExpensesUK£24.35m
Earnings-UK£20.32m

Last Reported Earnings

Dec 31, 2020

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin42.79%
Net Profit Margin-215.46%
Debt/Equity Ratio16.5%

How did CREO perform over the long term?

See historical performance and comparison

Valuation

Is Creo Medical undervalued compared to its fair value and its price relative to the market?

4.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CREO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CREO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CREO is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.

PE vs Market: CREO is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CREO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CREO is overvalued based on its PB Ratio (4.5x) compared to the GB Medical Equipment industry average (3.8x).


Future Growth

How is Creo Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-14.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CREO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CREO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CREO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CREO's revenue (41.9% per year) is forecast to grow faster than the UK market (5.4% per year).

High Growth Revenue: CREO's revenue (41.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CREO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Creo Medical performed over the past 5 years?

-28.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CREO is currently unprofitable.

Growing Profit Margin: CREO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CREO is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.

Accelerating Growth: Unable to compare CREO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CREO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (97.5%).


Return on Equity

High ROE: CREO has a negative Return on Equity (-32.35%), as it is currently unprofitable.


Financial Health

How is Creo Medical's financial position?


Financial Position Analysis

Short Term Liabilities: CREO's short term assets (£60.5M) exceed its short term liabilities (£21.8M).

Long Term Liabilities: CREO's short term assets (£60.5M) exceed its long term liabilities (£8.9M).


Debt to Equity History and Analysis

Debt Level: CREO's debt to equity ratio (16.5%) is considered satisfactory.

Reducing Debt: CREO's debt to equity ratio has increased from 0.9% to 16.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CREO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CREO has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 24.6% each year.


Dividend

What is Creo Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CREO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CREO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CREO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CREO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CREO's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.4yrs

Average management tenure


CEO

Craig Gulliford (50 yo)

9.67yrs

Tenure

UK£949,253

Compensation

Mr. Craig Jonathan Gulliford serves as the Chief Executive Officer of Creo Medical Limited since 2012. Mr. Gulliford served as Operations Director of Vix ACIS Limited (formerly ACIS Holdings Ltd). Mr. Gull...


CEO Compensation Analysis

Compensation vs Market: Craig's total compensation ($USD1.30M) is above average for companies of similar size in the UK market ($USD743.64K).

Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CREO's management team is seasoned and experienced (7.4 years average tenure).


Board Members

Experienced Board: CREO's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CREO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Creo Medical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Creo Medical Limited
  • Ticker: CREO
  • Exchange: AIM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£280.454m
  • Shares outstanding: 158.00m
  • Website: https://creomedical.com

Number of Employees


Location

  • Creo Medical Limited
  • Unit 2, Creo House
  • Beaufort Park
  • Chepstow
  • Gwent
  • NP16 5UH
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 17:44
End of Day Share Price2021/09/24 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.